Mirati Therapeutics Inc MRTX:NASDAQ

Last Price$82.73Cboe Real-Time Last Sale as of 9:32AM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-2.65(3.10%)
Bid (Size)$82.65 (100)
Ask (Size)$83.83 (1)
Day Low / High$82.73 - 83.01
Volume861.5 K

View Biotechnology IndustryPeer Comparison as of 08/17/2022


Mirati Therapeutics Inc ( NASDAQ )

Price: $82.73
Change: -2.65 (3.10%)
Volume: 861.5 K
9:32AM ET 8/17/2022

Denali Therapeutics Inc ( NASDAQ )

Price: $36.18
Change: -0.05 (0.14%)
Volume: 464.1 K
9:35AM ET 8/17/2022

Arrowhead Pharmaceuticals Inc ( NASDAQ )

Price: $47.12
Change: -0.51 (1.07%)
Volume: 468.7 K
9:36AM ET 8/17/2022

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Blueprint Medicines Corp ( NASDAQ )

Price: $54.05
Change: -14.50 (21.15%)
Volume: 231.5 K
9:36AM ET 8/17/2022

Read more news Recent News

Insider Sell: Mirati Therapeutics
4:22PM ET 8/16/2022 MT Newswires

Bruce L. A. Carter, Director, on August 12, 2022, sold 10,000 shares in Mirati Therapeutics (MRTX) for $854,899. Following the Form 4 filing with the SEC,...

--JMP Securities Adjusts Price Target on Mirati Therapeutics to $110 From $90, Maintains Market Outperform Rating
7:35AM ET 8/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Goldman Sachs Raises Mirati Therapeutics' Price Target to $195 From $188, Maintains Buy Rating
11:16AM ET 8/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (MRTX) MIRATI THERAPEUTICS Posts Q2 Revenue $5.4M
4:07PM ET 8/03/2022 MT Newswires


View all Commentary and Analysis

KRAS Drugs Fighting Uphill
2:14PM ET 8/08/2022 Seeking Alpha

Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q2 2022 Results - Earnings Call Transcript
10:11PM ET 8/03/2022 Seeking Alpha

Tracking Baker Brothers Portfolio - Q1 2022 Update
3:07AM ET 7/01/2022 Seeking Alpha

Mirati Therapeutics: Growth Cycle Transition
2:46AM ET 6/24/2022 Seeking Alpha

Company Profile

Business DescriptionMirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. View company web site for more details
Address3545 Cray Court
San Diego, California 92121
Number of Employees63
Recent SEC Filing08/16/20224
Chief Executive Officer & DirectorDavid D. Meek
President, Director & Head-Research & DevelopmentCharles M. Baum
Chief Financial & Accounting OfficerLaurie D. Stelzer
Chief Scientific Officer & Executive VPJames G. Christensen

Company Highlights

Price Open$82.88
Previous Close$85.38
52 Week Range$32.96 - 195.99
Market Capitalization$4.6 B
Shares Outstanding55.5 M
SectorHealth Technology
Next Earnings Announcement11/14/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$11.85
Beta vs. S&P 500N/A
Revenue$12.9 M
Net Profit Margin-824.57%
Return on Equity-53.24%

Analyst Ratings as of 08/13/2022

Consensus RecommendationConsensus Icon
Powered by Factset